Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category
Top Cited Papers
Open Access
- 7 April 2008
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 205 (4) , 799-810
- https://doi.org/10.1084/jem.20071258
Abstract
Experimental autoimmune uveitis (EAU) represents autoimmune uveitis in humans. We examined the role of the interleukin (IL)-23-IL-17 and IL-12-T helper cell (Th)1 pathways in the pathogenesis of EAU. IL-23 but not IL-12 was necessary to elicit disease by immunization with the retinal antigen (Ag) interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant. IL-17 played a dominant role in this model; its neutralization prevented or reversed disease, and Th17 effector cells induced EAU in the absence of interferon (IFN)-gamma. In a transfer model, however, a polarized Th1 line could induce severe EAU independently of host IL-17. Furthermore, induction of EAU with IRBP-pulsed mature dendritic cells required generation of an IFN-gamma-producing effector response, and an IL-17 response by itself was insufficient to elicit pathology. Finally, genetic deficiency of IL-17 did not abrogate EAU susceptibility. Thus, autoimmune pathology can develop in the context of either a Th17 or a Th1 effector response depending on the model. The data suggest that the dominant effector phenotype may be determined at least in part by conditions present during initial exposure to Ag, including the quality/quantity of Toll-like receptor stimulation and/or type of Ag-presenting cells. These data also raise the possibility that the nonredundant requirement for IL-23 in EAU may extend beyond its role in promoting the Th17 effector response and help provide a balance in the current Th1 versus Th17 paradigm.Keywords
This publication has 54 references indexed in Scilit:
- IL-25 regulates Th17 function in autoimmune inflammationThe Journal of Experimental Medicine, 2007
- IL-23 plays a key role inHelicobacter hepaticus–induced T cell–dependent colitisThe Journal of Experimental Medicine, 2006
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesThe Journal of Experimental Medicine, 2006
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunityThe Journal of Experimental Medicine, 2006
- Inter- and Intramolecular Epitope Spreading in Equine Recurrent UveitisInvestigative Opthalmology & Visual Science, 2006
- Indoleamine 2,3 dioxygenase and regulation of T cell immunityBiochemical and Biophysical Research Communications, 2005
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003